Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
出版年份 2020 全文链接
标题
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e001153
出版商
BMJ
发表日期
2020-10-24
DOI
10.1136/jitc-2020-001153
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor
- (2020) Kevin Smart et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
- (2019) Sandra M. M. Irenaeus et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages
- (2019) C A Gomez-Roca et al. ANNALS OF ONCOLOGY
- CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages
- (2019) Antonin Papin et al. LEUKEMIA
- Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
- (2018) Curtis J. Perry et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
- (2018) Sabine Hoves et al. JOURNAL OF EXPERIMENTAL MEDICINE
- SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
- (2018) Juneko E. Grilley-Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
- (2018) David L. Bajor et al. OncoImmunology
- Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
- (2017) Karla R. Wiehagen et al. Cancer Immunology Research
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
- (2016) E Eriksson et al. GENE THERAPY
- CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
- (2016) Katelyn T. Byrne et al. JOURNAL OF IMMUNOLOGY
- An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
- (2015) B. von Tresckow et al. CLINICAL CANCER RESEARCH
- CSF-1/CSF-1R targeting agents in clinical development for cancer therapy
- (2015) Carola H Ries et al. CURRENT OPINION IN PHARMACOLOGY
- CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
- (2015) Philippe A Cassier et al. LANCET ONCOLOGY
- A product of independent beta probabilities dose escalation design for dual-agent phase I trials
- (2015) Adrian P. Mander et al. STATISTICS IN MEDICINE
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor Model
- (2013) Andrea Khong et al. JOURNAL OF IMMUNOTHERAPY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer
- (2012) Andrea Khong et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature
- (2012) Qiong-wen Zhang et al. PLoS One
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
- (2011) Jens Rüter et al. CANCER BIOLOGY & THERAPY
- AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial
- (2010) P.-U. Malmstrom et al. CLINICAL CANCER RESEARCH
- Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma
- (2009) Inigo Espinosa et al. AMERICAN JOURNAL OF PATHOLOGY
- The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma
- (2009) A. H. Beck et al. CLINICAL CANCER RESEARCH
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer
- (2009) Hiroshi Kurahara et al. JOURNAL OF SURGICAL RESEARCH
- Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
- (2009) Erica L Carpenter et al. Journal of Translational Medicine
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started